ArticleScientific reports2025
BRCA1 expression in ovarian cancer and its relationship with clinicopathological characteristics and prognosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the relationship between breast cancer susceptibility 1 (BRCA1) and clinicopathological characteristics and prognosis of ovarian cancer patients. Cancer tissue samples, paracancerous tissue samples and clinical data of 195 patients with ovarian cancer diagnosed in our hospital from January 2016 to August 2021 were collected and sorted out. The expression of BRCA1 protein in ovarian cancer was retrieved from the Clinical Proteomic Tumor Analysis Consortium(CPTAC) dataset of the Ualcan database; the expression of BRCA1 protein was detected by immunohistochemistry; Kaplan-Meier curve was drawn to analyze the relationship between BRCA1 protein expression level and 3-year survival rate of ovarian cancer patients; multivariate Cox regression analysis was used to examine the prognostic factors of ovarian cancer patients. There was no obvious difference in BRCA1 protein expression level between ovarian cancer tissues and normal ovarian tissues through the analysis of the CPTAC database by Ualcan (P > 0.05). The positive rate of BRCA1 protein in ovarian cancer tissues was obviously lower than that in adjacent tissues (P < 0.05). The positive rate of BRCA1 protein in ovarian cancer patients with FIGO stage III + IV, poorly differentiated tissues and lymph node metastasis was obviously lower than that in ovarian cancer patients with International Federation of Gynecology and Obstetrics (FIGO) stage I + II, moderately/highly differentiated tissues and no lymph node metastasis (P < 0.05). The 3-year survival rate of patients with negative expression of BRCA1 protein was obviously lower than that of patients with positive expression of BRCA1 protein (P < 0.05). The proportions of patients with FIGO stage III + IV, poor tissue differentiation and lymph node metastasis in death group were higher than those in survival group (P < 0.05). Lymph node metastasis was an independent risk factor for death of ovarian cancer patients within 3 years, BRCA1 was a protective factor for death of ovarian cancer patients within 3 years (P < 0.05). BRCA1 is low expressed in ovarian cancer, it is related to FIGO stage, tissue differentiation and lymph node metastasis, which has important clinical value in evaluating the patient's condition and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.